Background The risk for lymph node metastasis and the prognostic significance of pedunculated-type T1 colorectal carcinomas (CRCs) require further study. We aimed to assess the validity of the 2014 Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines based on long-term outcomes of pedunculated-type T1 CRCs. Methods In this multicenter retrospective cohort study, we examined 176 patients who underwent resection endoscopically or surgically at 14 institutions between January 1990 and December 2010. Patients meeting the JSCCR curative criteria were defined as ''endoscopically curable (e-curable)'' and those who did not were ''none-curable''. We evaluated the prognosis of 116 patients (58 e-curable, 58 non-e-curable) who were observed for [5 years after treatment.
Abstract
Background The risk for lymph node metastasis and the prognostic significance of pedunculated-type T1 colorectal carcinomas (CRCs) require further study. We aimed to assess the validity of the 2014 Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines based on long-term outcomes of pedunculated-type T1 CRCs. Methods In this multicenter retrospective cohort study, we examined 176 patients who underwent resection endoscopically or surgically at 14 institutions between January 1990 and December 2010. Patients meeting the JSCCR curative criteria were defined as ''endoscopically curable (e-curable)'' and those who did not were ''none-curable''. We evaluated the prognosis of 116 patients (58 e-curable, 58 non-e-curable) who were observed for [5 years after treatment.
Results Overall incidence of lymph node metastasis was 5 % (4/81; 95 % confidence interval 1.4-12 %: three cases of submucosal invasion depth C1000 lm [stalk invasion] and lymphatic invasion, one case of head invasion and budding grade 2/3). There was no local or metastatic recurrence in the e-curable patients, but six of them died of another cause (observation period, 80 months). There was no local recurrence in the non-e-curable patients; however, distant metastasis was observed in one patient. Death due to the primary disease was not observed in non-e-curable patients, but six of them died of another cause (observation period, 72 months).
Conclusions Our data support the validity of the JSCCR curative criteria for pedunculated-type T1 CRCs. Endoscopic resection cannot be considered curative for pedunculated-type T1 CRC with head invasion alone.
Introduction
As a result of recent advances in endoscopic instruments and techniques, the proportion of T1 colorectal carcinoma (CRC) initially treated by endoscopic resection (ER) has been increasing [1] [2] [3] [4] [5] . However, lymph node (LN) metastasis occurs in approximately 10 % of T1 CRCs [4] [5] [6] [7] [8] ; furthermore, the rate of LN metastasis is reportedly 3.5-7.5 % in pedunculated-type T1 CRC [9] [10] [11] [12] [13] [14] [15] [16] [17] . Despite the low incidence of LN metastasis, surgical resection with regional LN dissection is considered the standard treatment for T1 CRC [18] . According to the Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines, the curative criteria for T1 CRC after ER are well/moderately differentiated or papillary carcinoma, no vascular invasion, submucosal (SM) invasion depth \1000 lm, and budding grade 1, because of the very low risk of LN metastasis associated with these pathological features [19] . In Western countries, Haggitt's classification is frequently used to define the depth of invasion of pedunculated-type T1 CRC [20] . Haggitt and colleagues stratified the level of carcinoma invasion according to the following criteria: level 0, carcinoma in situ (i.e., no extension below the muscularis mucosae); level 1, invasion through the muscularis mucosae but limited to the head of the polyp (i.e., above the junction between the adenoma and its stalk); level 2, invasion at the level of the neck (i.e., the junction between the adenoma and its stalk); level 3, invasion of any part of the stalk; and level 4, invasion into the submucosa of the bowel wall below the stalk. The authors concluded that the risk of metastasis or local recurrence is low when the level is \4.
A project conducted by JSCCR reported a rate of LN metastasis of 0 % in pedunculated T1 CRCs with invasion above the boundary of Haggitt's level 2 (Haggitt's line) and in those that had invaded beyond Haggitt's line to a SM depth of \3000 lm with no lymphatic invasion [14] . In a retrospective multicenter study that enrolled 384 pedunculated-type T1 CRC patients treated by ER or surgical resection, Matsuda et al. concluded that all cases with LN metastasis or recurrence were in those with carcinoma that had invaded beyond Haggitt's line [15] . Several studies have reported long-term outcomes for T1 CRCs treated with ER [13, [21] [22] [23] [24] [25] ; however, the JSCCR guidelines do not clearly outline the long-term outcomes of patients with T1 CRC who underwent ER or surgical resection. Compared with non-pedunculated T1 CRCs, pedunculated-type T1 CRCs tend to be easier to detect, diagnose, and treat by initial ER as total excisional biopsy [3] . However, the risk of LN metastasis and the prognostic significance of pedunculated-type T1 CRCs have not been studied adequately. This study aimed to assess the clinical validity of the JSCCR guidelines based on long-term outcomes for pedunculated-type T1 CRCs after ER or surgical resection.
Patients and methods

Patients
We evaluated the clinicopathological characteristics of 176 patients with 176 pedunculated-type T1 CRCs [138 (78 %) men, mean age 64 (range, 29-84) years, median follow-up period 105.5 months] resected endoscopically or surgically at Hiroshima University Hospital and 13 affiliated hospitals between January 1990 and December 2010. Patients who met the JSCCR curative criteria were defined as ''endoscopically curable (e-curable)'' and those who did not were defined as ''non-e-curable''. We also evaluated the prognosis of the 116 patients (58 e-curable, 58 non-e-curable) who were followed up for [5 years after treatment, with a mean follow-up duration of 124 ± 77 months. Patients who were eligible for this study had pathologically proven adenocarcinoma invading through the muscularis mucosae into the SM layer but not extending deeply into the muscularis propria. Patients with previous or synchronous advanced CRC; multiple, early, invasive CRCs; inflammatory bowel disease; hereditary non-polyposis CRC; and familial adenomatous polyposis were excluded from this study. Patients who underwent surgical resection without LN dissection (transanal endoscopic microsurgery and local resection) as initial treatment for T1 CRC were also excluded. The study protocol was approved by the Ethics Committee of Hiroshima University and complied with the guidelines of the Ministry of Health, Labour and Welfare of the Japanese Government.
Indication and procedure for ER
ER methods consist of polypectomy or endoscopic mucosal resection. Patients enrolled in this study were treated according to the JSCCR guidelines [19] , which specify that ER should not be applied for early CRC if en bloc removal is impossible or for clinical T1 CRC with deep invasion of the submucosa prior to treatment.
Indications for additional surgical treatment after ER
The JSCCR guidelines state that a positive deep tumor margin is an absolute indication for additional surgery after ER. Additional surgical treatment after ER should be considered when at least one of the following is found: (1) SM invasion depth C1000 lm; (2) positive vascular invasion; (3) poorly differentiated adenocarcinoma, signet ring cell carcinoma, or mucinous carcinoma; and (4) budding grade 2/3 at the deepest part of SM invasion [19] . A budding is defined as a single cancer cell or a cluster of \5 cells along the invasion margin, and budding is graded per microscopic field at 2009 magnification (i.e., grade 1, 0-4; grade 2, 5-9; grade 3, C10 buds) [7] .
The JSCCR guidelines clearly state that additional surgical treatment should be performed only after systematically evaluating the predicted curability based on various LN metastasis risk factors and the patient's condition (age, physical performance, and presence of adverse event, etc.) and after obtaining informed consent from the patients [19] .
Method for measuring depth of SM invasion
According to the JSCCR guidelines [19] , the method used for measurement of SM depth is as follows. When it is possible to identify or estimate the location of the muscularis mucosae, the depth of SM invasion is measured from the lower border of the muscularis mucosae of the lesion, irrespective of macroscopic type. When it is not possible to identify or estimate the location of the muscularis mucosae, the depth of SM invasion is measured from the surface of the lesion. The phrase ''possible to identify or to estimate'' means that there is no ''deformity'', that is, no disarray, dissection, rupture, fragmentation, etc., of the muscularis mucosae as a result of SM invasion. If a deformed muscularis mucosa is used as the measurement baseline, the depth of SM invasion may be underestimated. Although judging whether deformity is present is not always straightforward, if a desmoplastic reaction is present around the muscularis mucosae, it is assumed to be ''deformed''. For pedunculated-type CRCs with a tangled muscularis mucosae, the depth of SM invasion is measured from Haggitt's line. Invasion within the head alone is defined as ''head invasion''.
Clinicopathological features and outcomes of T1 CRC
We assessed demographic and clinical characteristics (tumor location, tumor size, gross type, histologic type, SM invasion depth, vertical margin, lymphatic invasion, venous invasion, and budding grade) and long-term outcomes of pedunculated-type T1 CRCs after endoscopic or surgical resection. All pathological slides of the tumors were reassessed by an experienced gastrointestinal pathologist (F.S.) who was blinded to the clinical outcomes. The incidence of LN metastasis of surgically treated lesions was analyzed. Physical examination, chest radiography, computed tomography (CT) of the abdomen and pelvis, and blood tests including carcinoembryonic antigen level were performed every 6 months postoperatively for the first 3 years and every 12 months thereafter and a total colonoscopy was performed every year, in principle. Recurrence was recorded as local, distant, and overall recurrence. Recurrent lesions were identified by colonoscopy, CT, or transabdominal ultrasound. Local recurrence after surgical resection was defined as recurrence within the surgical field for T1 CRC or within the pelvis for T1 rectal carcinoma.
Statistical analysis
Values are reported as means (with standard deviations). Fisher's exact test was used to compare categorical variables. Analyses were performed with JMP Statistical software, version 9.02 (SAS Institute, Cary, NC, USA). p values \0.05 were considered statistically significant. There was no adjustment of nominal p values to correct for multiple testing of outcome data arising from individual patients, because the main focus of this research was exploratory in nature. Disease-free survival and overall survival rates were calculated by the Kaplan-Meier method.
Results
The demographics and clinical characteristics of pedunculated-type T1 CRC cases are shown in Table 1 . The treatment method was ER alone in 95 cases (54 %), additional surgery after ER in 66 (38 %), and surgical resection alone in 15 (8 %). Initial ER was performed in 161 (91 %) cases and the histological en bloc resection rate was 96 % (154/161). The rates of post-ER bleeding and perforation were 2 (3/161) and 0 % (0/161), respectively ( Table 2 ). Most tumors [173 (98 %)] were well-or moderately differentiated adenocarcinomas, but three (2 %) were poorly differentiated adenocarcinomas. Mean tumor size was 17.5 ± 3.5 (range, 6-75) mm, with 137 (78 %) located in the left colon, 21 (12 %) in the right colon, and 18 (10 %) in the rectum. SM invasion \1000 lm was observed in 100 cases, with head invasion in 78 (44 %) and stalk invasion in 19 (11 %) while invasion [1000 lm was observed in 76 cases, with stalk invasion in 50 (28 %).
There were 38 cases of lymphatic invasion (22 %), 14 of venous invasion (8 %), and 24 of budding grade 2/3 (14 %) ( Table 1) . Among T1 CRCs with invasion above Haggitt's line (n = 107), the rates of SM invasion depth C1000 lm and venous invasion were 24 (26/107) and 5 % (5/107), respectively, compared with 72 (50/69) and 13 % (9/69) of T1 CRCs that had invaded beyond Haggitt's line (n = 69) (p \ 0.05). The rate of lymphatic invasion of T1 CRCs with histological invasion above Haggitt's line was 17 % (18/107), compared with 29 % (20/69) of T1 CRC that had invaded beyond Haggitt's line (p = 0.06). A total of 82 patients (47 %) met the JSCCR curative criteria. The overall incidence of LN metastasis was 5 % [4/81; 95 % confidence interval (CI) 1.4-12 %; three cases of SM invasion depth C1000 lm (stalk invasion) and lymphatic invasion, one case of head invasion and budding grade 2/3] ( Table 3 ). The incidence of LN metastasis of e-curable and non-e-curable lesions was 0 % (0/21; 95 % CI 0-13 %) and 7 % (4/60; 95 % CI 1.8-16.2 %), respectively. There was no local or metastatic recurrence in any of the e-curable patients, but six of them died of another cause: three, another organ carcinoma; one, myocardial infarction; one, cerebral hemorrhage; one, decrepitude; average observation period of 80 months. There was no local recurrence in the non-e-curable patients; however, distant metastasis was observed in one patient [2 %; well-differentiated adenocarcinoma, SM invasion depth C1000 lm (stalk invasion), budding grade 1, ly1, v0, HM0, VM0], with carcinoma recurring in the liver and lung 7 and 36 months after additional surgery, respectively (Table 3) . Death due to primary disease was not observed in non-e-curable patients at the latest follow-up, but six of them died of another cause (three of another organ carcinoma, two of myocardial infarction, and one of decrepitude; average observation period of 72 months). As shown in Fig. 1 , a very low incidence of recurrence was observed in patients with pedunculated-type CRC. The corresponding overall survival rates of the e-curable patients were 94.7, 100, and 100 % in the ER group, ER plus surgical resection group, and surgical resection group, respectively, while the corresponding overall survival rates of the non-e-curable patients were 90.9, 100, and 100 % (Fig. 2) . None of the patients had adverse events after ER or postoperative adverse events requiring emergency surgery, including perforation or bleeding, and no mortality occurred at the time of surgical resection after ER.
Discussion
This is the first multicenter retrospective cohort study that assessed the clinical validity of the JSCCR guidelines based on long-term outcomes of pedunculated-type T1 CRCs after ER or surgical resection. The results of this study support the validity of the JSCCR curative criteria for pedunculated-type T1 CRCs after ER because e-curable patients showed no increased risk for recurrence and had good outcomes. Previously, histopathological factors such as deep SM invasion, poor differentiation, angiolymphatic invasion, presence of a poorly differentiated area and muconodules at the site of deepest invasion, and budding grade were reported to be associated with LN metastasis in T1 CRC [7, 14, 19, 26] . A few studies showed that SM depth was not significantly related to LN metastasis in patients with T1 CRC [8, 21, 24, 27, 28] . We previously reported an incidence of LN metastasis of only 1.2 % (95 % CI, 0.25-3.48 %) in T1 CRC without three of the four risk factors (i.e., all except SM invasion depth \1000 lm) for LN metastasis according to the JSCCR guidelines [8] . Measurement of the depth of SM invasion is relatively simple in cases of sessile-type T1 CRC [19] ; however, it is relatively complicated in pedunculated-type T1 CRC due to the presence of stalks, the varying length of these stalks and tangled muscularis mucosae. Since Haggitt et al. [20] proposed a classification of the level of invasion of CRC arising from polyps in 1985, the classification of SM invasion has been widely used in pathological evaluation. Although this classification is very simple, the 129 analyzed cases consisted of both non-pedunculated and pedunculated-type T1 CRCs, with only 70 cases of pedunculated-type T1 CRC [20] . Therefore, the use of Haggitt's classification tends to lead to over-treatment of cases without LN metastasis and it does not consider recently identified risk factors such as tumor budding [7] . In a retrospective multicenter study involving 384 
Alive Well well-differentiated adenocarcinoma pedunculated-type T1 CRC patients treated with ER or surgical resection, Matsuda et al. [15] reported that the incidence of LN metastasis of pedunculated-type T1 CRC was 0 % (0/101) with invasion above Haggitt's line and 6.2 % (8/129) with invasion beyond Haggitt's line, and they suggested that pedunculated-type T1 CRC with invasion above Haggitt's line could be managed by ER alone. However, the follow-up period of their study was short, and there was a lack of data on tumor budding, which has been identified as an important risk factor for LN metastasis.
A meta-analysis revealed that lymphatic vessel invasion identified by an anti-human podoplanin antibody and tumor budding were significantly associated with T1 CRC LN metastasis [29] . Several studies with a small number of analyzed cases have reported the rate of LN metastasis of pedunculated-type T1 CRCs with invasion above Haggitt's line (Table 4) [10, 12, 15, [30] [31] [32] . In Collacchio's series, the incidence of LN metastasis of T1 CRCs with invasion above Haggitt's line was 29 % (5/ 17). The five patients with LN metastasis belonged to their case series in which two had documented carcinoma within the lymphatics of the polyp and one had an invasive anaplastic carcinoma [31] . Fenoglio et al. reported two pedunculated-type T1 CRCs with LN metastasis in which carcinomatous invasion was above Haggitt's line and that both cases had lymphatic invasion [33] . Kitajima et al. [14] reported that LN metastasis was observed in three cases with invasion above Haggitt's line and a prediction of the absence of LN metastasis based on SM depth alone was considered difficult. All three cases with invasion above Haggitt's line and LN metastasis were positive for lymphatic invasion. In the present study, the overall incidence of LN metastasis was 5 % (4/81). Our results showed that one of four cases with LN metastasis had ''head invasion''. Therefore, ER cannot be Fig. 1 Kaplan-Meier curves of disease-free survival of patients with pedunculated-type T1 colorectal carcinoma. Disease-free survival (DFS) rates in the e-curable patients were all 100 %, regardless of treatment with endoscopic resection (ER) alone, ER plus additional surgical resection, or surgical resection alone. Disease-free survival rates were 100, 97.2, and 100 % in the non-e-curable patients treated with endoscopic resection (ER) alone, ER plus additional surgical resection, and surgical resection alone, respectively, with no significant differences between the groups (p = 0.74) Fig. 2 Kaplan-Meier curves of overall survival of the non-e-curable patients. Overall survival (OS) rates of the e-curable patients treated with ER alone, ER plus additional surgical resection, and surgical resection alone were 94.7, 100, and 100 %, respectively, with no significant differences between the groups (p = 0.81). OS rates of the non-e-curable patients treated with ER alone, ER plus additional surgical resection, and surgical resection alone were 90.9, 100, and 100 %, respectively, with no significant differences between the groups (p = 0.10) J Gastroenterol (2016) 51:702-710 707 considered curative for pedunculated-type T1 CRC with head invasion alone, as defined in the JSCCR guidelines. The JSCCR criteria were established based on an analysis of histologic data of T1 CRC in surgically resected specimens [14] , and there have been few reports on surveillance data after ER for T1 CRC [13, [21] [22] [23] 34] . Recurrence in patients with T1 CRC after surgical curative resection has also been reported [6, 16] . As yet, the characteristics and types of recurrence remain unclear. In this study, a very low incidence of recurrence was observed in patients with pedunculated-type CRC. It is possible that no significance was seen in disease-free survival rates because additional surgery restrained the local or LN recurrence of carcinomas in non-e-curable patients. However, distant metastasis was observed in one patient with carcinoma recurring in the liver and lung 7 and 36 months after additional surgery with LN dissection.
The overall survival rates was low only in the ER, although overall survival rates showed no significance in the non-e-curable patients treated with ER alone, ER plus additional surgical resection, and surgical resection alone, respectively. This finding is attributable to the fact that patients treated with ER alone included non-e-curable patients who could not undergo surgery because of anesthesia concerns and/or advanced age.
Our study revealed that 161 (91 %) pedunculated-type T1 CRC cases received ER as the initial treatment; histological en bloc resection rate was 96 % (154/161); the rate of adverse events was extremely low; and there were no local recurrence cases. These results suggested pedunculated-type T1 CRCs could be managed by polypectomy/ EMR alone when en bloc resection is possible.
Endoscopic submucosal dissection (ESD) is regarded as a reliable method for en bloc resection regardless of tumor size and a possible standard technique for total excisional biopsy for clinical T1 CRC after an accurate preoperative diagnosis and precise histopathological diagnosis are reached [3] . ESD is an effective procedure for removal of large pedunculated-type CRC when it is difficult to correctly position the snare over the stalk for en bloc resection [35] . The JSCCR guidelines clearly state that additional treatment should be performed only after systematically evaluating the predicted curability based on various LN metastasis risk factors and the patient's background (e.g., age, concomitant disease, operative method, patient's wishes, life expectancy, and performance status) and after obtaining informed consent from the patient [19] . The findings of the present study demonstrated that we should follow the JSCCR guidelines after treatment for pedunculated-type T1 CRC.
This study has some limitations. First, this study was a multicenter retrospective cohort study based on clinical records. Second, this study might be affected by selection bias because it was not randomized. Third, we reevaluated the pathological diagnosis and features including tumor budding; however, we did not reevaluate lymphovascular invasion using immunohistochemical staining for all cases. Routine use of immunohistochemistry should be considered in future retrospective studies. Fourth, the statistical power was not sufficient to discern small differences in the group analysis of more comprehensive pathologic factors. Large-scale multicenter prospective investigations are needed to evaluate the long-term outcomes of T1 CRC in the near future.
In conclusion, our data support the validity of the JSCCR curative criteria (well/moderately differentiated or papillary carcinoma, no vascular invasion, SM invasion depth \1000 lm, and budding grade 1) for pedunculatedtype T1 CRCs after ER. ER cannot be considered curative for pedunculated-type T1 CRC with head invasion alone. Additional surgery after ER should be considered only after taking into account the patient's condition and the concrete risk of LN metastasis in each case.
